Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Berkowitz

Showing results (341-350 of 497) with videos related to

Pageof 50
Sort By:
Journal of the American College of Cardiology|August 13, 2021
Rivaroxaban in Patients With Recent Peripheral Artery Revascularization and Renal Impairment: The VOYAGER PAD TrialJudith Hsia, Michael Szarek, Sonia Anand, et al.
Circulation|June 3, 1997
Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I InvestigatorsS D Berkowitz, C B Granger, K S Pieper, et al.
American Heart Journal|June 30, 2000
Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockadeD J Kereiakes, S D Berkowitz, A M Lincoff, et al.
Vascular Medicine (London, England)|April 30, 2025
Prescription of aspirin plus low-dose rivaroxaban in patients with peripheral artery disease after lower-extremity revascularizationMario Enrico Canonico, Connie N Hess, Sivan Naveh, et al.
Archives of Surgery (Chicago, Ill. : 1960)|November 1, 1981
Long-term results of transluminal angioplasty of the iliac and femoral arteriesR K Spence, D B Freiman, R Gatenby, et al.
Journal of Thrombosis and Thrombolysis|April 26, 2003
The determinants of activated partial thromboplastin time, relation of activated partial thromboplastin time to clinical outcomes, and optimal dosing regimens for heparin treated patients with acute coronary syndromes: a review of GUSTO-IIbMichael S Lee, Andreas U Wali, Venu Menon, et al.
Critical Care Medicine|May 29, 2003
The physician's role in discussing organ donation with familiesMichael A Williams, Pamela A Lipsett, Cynda H Rushton, et al.
The Journal of Infectious Diseases|October 1, 1987
Safety and immunogenicity of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine (PRP-D) in infantsM L Lepow, R M Barkin, C D Berkowitz, et al.
Stroke|April 17, 2020
Potential Embolic Sources and Outcomes in Embolic Stroke of Undetermined Source in the NAVIGATE-ESUS TrialGeorge Ntaios, Lesly A Pearce, Roland Veltkamp, et al.
Thrombosis and Haemostasis|December 8, 2010
Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studiesAlexander G G Turpie, Michael Rud Lassen, Bengt I Eriksson, et al.
Pageof 50

Showing results (341-350 of 497) with videos related to

Sort By:
Pageof 50
Journal of the American College of Cardiology|August 13, 2021
Rivaroxaban in Patients With Recent Peripheral Artery Revascularization and Renal Impairment: The VOYAGER PAD TrialJudith Hsia, Michael Szarek, Sonia Anand, et al.
Circulation|June 3, 1997
Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I InvestigatorsS D Berkowitz, C B Granger, K S Pieper, et al.
American Heart Journal|June 30, 2000
Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockadeD J Kereiakes, S D Berkowitz, A M Lincoff, et al.
Vascular Medicine (London, England)|April 30, 2025
Prescription of aspirin plus low-dose rivaroxaban in patients with peripheral artery disease after lower-extremity revascularizationMario Enrico Canonico, Connie N Hess, Sivan Naveh, et al.
Archives of Surgery (Chicago, Ill. : 1960)|November 1, 1981
Long-term results of transluminal angioplasty of the iliac and femoral arteriesR K Spence, D B Freiman, R Gatenby, et al.
Journal of Thrombosis and Thrombolysis|April 26, 2003
The determinants of activated partial thromboplastin time, relation of activated partial thromboplastin time to clinical outcomes, and optimal dosing regimens for heparin treated patients with acute coronary syndromes: a review of GUSTO-IIbMichael S Lee, Andreas U Wali, Venu Menon, et al.
Critical Care Medicine|May 29, 2003
The physician's role in discussing organ donation with familiesMichael A Williams, Pamela A Lipsett, Cynda H Rushton, et al.
The Journal of Infectious Diseases|October 1, 1987
Safety and immunogenicity of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine (PRP-D) in infantsM L Lepow, R M Barkin, C D Berkowitz, et al.
Stroke|April 17, 2020
Potential Embolic Sources and Outcomes in Embolic Stroke of Undetermined Source in the NAVIGATE-ESUS TrialGeorge Ntaios, Lesly A Pearce, Roland Veltkamp, et al.
Thrombosis and Haemostasis|December 8, 2010
Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studiesAlexander G G Turpie, Michael Rud Lassen, Bengt I Eriksson, et al.
Pageof 50